F-1/A: Regentis Biomaterials Launches IPO to Fund Pivotal Trial for Knee Cartilage Repair Product GelrinC Amidst Going Concern Doubts

Regentis Biomaterials Ltd., an Israeli regenerative medicine company, is seeking to raise approximately $9.1 million through an initial public offering to advance its lead product candidate, GelrinC, towards FDA approval for knee cartilage repair, despite a history of operating losses and a going concern qualification.

Summary

• Regentis Biomaterials Ltd. is a regenerative medicine company focused on orthopedic treatments using its Gelrin hydrogel platform, with its lead product candidate, GelrinC, designed for articular knee cartilage repair.
• GelrinC is a cell-free, off-the-shelf hydrogel implant that aims to regenerate hyaline-like cartilage, offering a simple, economic procedure with potentially quick recovery and long-term outcomes, unlike traditional microfracture surgery which produces fibrous cartilage.
• The company completed a Pilot Study on 56 patients in Northern Europe and Israel, demonstrating superior pain reduction and improvement in KOOS and VAS scores compared to historical microfracture data, with positive outcomes sustained for up to four years.
• Regentis is currently conducting a pivotal clinical trial in the United States and Europe under an FDA-approved Investigational Device Exemption (IDE), having recruited and treated 47 out of 80 required patients, with 41 having completed the two-year follow-up.
• The pivotal trial utilizes historical microfracture data from TiGenix NV as a control, which the FDA has allowed for a more efficient and less costly trial.
• The company expects to complete patient enrollment for the pivotal trial by the end of 2025 and anticipates submitting its Pre-Market Approval (PMA) application to the FDA by the end of 2027.
• Regentis reported a net income of $4.8 million for the year ended December 31, 2024, primarily due to a $2.306 million Horizon 2020 Grant and positive changes in the fair value of convertible notes and warrant liability, contrasting with a net loss of $4.1 million in 2023.
• As of December 31, 2024, the company had an accumulated deficit of $42.1 million and negative working capital of $6.0 million, with cash and cash equivalents of $0.229 million.
• The company plans to raise approximately $9.1 million in net proceeds from this initial public offering, with an anticipated price range of $10.00 to $12.00 per Ordinary Share (midpoint $11.00).
• Proceeds are allocated for development activities ($4.5 million for pivotal trial and PMA), operations ($1.0 million), R&D ($0.5 million), EU marketing development ($0.5 million), repayment of various loans ($1.1 million), a payment to the Chairman ($0.25 million), and a CSL settlement payment ($0.43 million), with the remainder for working capital and general corporate purposes.
• The company's Ordinary Shares have been approved for listing on the NYSE American under the symbol RGNT.
• Regentis is an emerging growth company and a foreign private issuer, allowing it to take advantage of reduced public company reporting requirements and an extended transition period for new accounting standards.

Sentiment

Score: 4

Explanation: The company presents a promising product (GelrinC) with positive pilot study results and a clear path to FDA approval, addressing an unmet market need. However, significant financial challenges, including a history of operating losses, substantial accumulated deficit, negative working capital, and a going concern qualification, weigh heavily. The reliance on IPO proceeds for continued operations and the competitive landscape introduce considerable risk, leading to a cautious sentiment.

Positives

• GelrinC has received a CE mark in Europe in 2017, indicating European approval for the device.
• The Pilot Study demonstrated GelrinC's superiority over microfracture surgery, showing 100% greater improvement in pain reduction at two years and continued improvement for four years.
• The FDA granted an Investigational Device Exemption (IDE) for GelrinC's pivotal trial, allowing PMA submission with two-year follow-up data from 80 patients and permitting the use of historical microfracture data as a control, which makes the trial more efficient and less costly.
• The company has a robust intellectual property portfolio with 34 issued patents and 4 pending applications covering compositions, delivery devices, surgical methods, and manufacturing features, with newer patents extending protection beyond the earliest expiring ones.
• The company reported a net income of $4.8 million in 2024, a significant improvement from a $4.1 million net loss in 2023, driven by a Horizon 2020 Grant and favorable fair value adjustments of financial instruments.
• GelrinC is an 'off-the-shelf' product, which is currently lacking in the U.S. cartilage repair market, potentially offering a significant competitive advantage.
• The procedure for GelrinC is described as simple, requiring approximately 10 minutes, with an average two-week recovery period, which is significantly shorter and less invasive than competing cellular therapies like MACI.
• The company plans to build on its Gelrin platform technology to broaden its product base, including GelrinP for smaller joints and GelrinV for osteoarthritis, indicating future growth potential.

Negatives

• The company has a limited operating history and has not generated any revenue from product sales to date, relying primarily on equity financing and convertible loans.
• Despite a net income in 2024 due to non-operating items, the company has incurred significant operating losses since its inception and anticipates continued losses for the foreseeable future.
• The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern, indicating a need for significant additional funding.
• As of December 31, 2024, the company had a negative working capital of $6.0 million, highlighting liquidity challenges.
• The company is highly dependent on contract manufacturing organizations (CMOs) and single raw material suppliers, making it vulnerable to supply shortages, increased costs, and quality issues.
• The company's business plan is dependent on third-party service providers, and their failure to maintain high-quality service could impair product utility and reputation.
• The size and expected growth of the addressable market for GelrinC have not been established with precision and may be smaller than estimated, or the company may not capture sufficient market share.
• The company faces intense competition from large, diversified medical device and pharmaceutical companies, as well as smaller companies, and potential competition from alternative therapies.
• The company is highly dependent on key members of its executive management team, and their inability to be retained could impede business plans and growth strategies.
• The company's management team has limited experience managing a public company, which could lead to challenges in complying with complex public company laws and scrutiny.
• The company is subject to extensive government regulation and oversight, and failure to comply could result in enforcement actions, penalties, or product recalls.
• The earliest patent family covering Gelrin technology is set to expire in December 2025, which could expose the company to increased competition if newer patents do not provide sufficient protection.

Risks

• The company has a limited operating history and has incurred significant operating losses since inception, anticipating continued losses for the foreseeable future, and may never be profitable.
• Even if this offering is successful, the company will need to raise substantial additional funding, which may not be available on acceptable terms or at all, potentially requiring curtailment, delay, or discontinuation of product development.
• The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern, which could prevent new financing on reasonable terms.
• The company may not succeed in advancing GelrinC's development, achieving manufacturing stability and capacity, demonstrating sufficient clinical evidence, or commercializing its product to generate significant revenues.
• Clinical failure can occur at any stage of clinical development, and past clinical experience does not necessarily predict future results, potentially requiring further clinical validation or leading to unfavorable results in later trials.
• The company operates in a very competitive business environment, and inability to compete successfully against existing or potential competitors could adversely affect business, financial condition, and results of operations.
• Inability to successfully commercialize GelrinC or any subsequent decline in demand for it could severely harm the company's ability to generate revenues, as it expects to derive most revenues from this product.
• If healthcare professionals do not recommend GelrinC to their patients, it may not achieve market acceptance, and the company may not become profitable.
• The company is dependent upon contract manufacturing organizations and raw material suppliers, making it vulnerable to supply shortages, increased costs, and quality or compliance issues.
• The company may not be able to replace its current manufacturing capabilities in a timely manner if prolonged interruptions occur.
• The company's business plan relies on certain assumptions about the market for its product, but the addressable market may be smaller than estimated, or the company may not be able to capture additional market share.
• Reliance on third parties to manage clinical studies and trials, perform data collection and analysis, and enroll patients may lead to costs and delays beyond the company's control.
• The company may not be able to generate sufficient cash to service all of its indebtedness and may be forced to take other actions to satisfy obligations, which may not be successful.
• Business, operating results, and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.
• High dependence on key members of the executive management team means inability to retain these individuals could impede business plan and growth strategies.
• Exchange rate fluctuations between the U.S. dollar and the New Israeli Shekel and inflation may negatively affect results of operations, and hedging currency risks may not be successful.
• The outcome of any future claims and litigation could have a material adverse impact on the business, financial condition, and results of operations.
• Certain directors, director nominees, and/or officers may have interests that compete with the company and its shareholders.
• The management team has limited experience managing a public company, which could divert attention and adversely affect business.
• Any resurgence of the COVID-19 pandemic could adversely affect the business, financial condition, and results of operations.
• If the company is unable to obtain patent protection for its products, or if patents and other intellectual property rights do not adequately protect products, it may be unable to gain significant market share and operate profitably.
• Obtaining and maintaining patent protection depends on compliance with various procedures, and patent protection could be reduced or eliminated for non-compliance.
• Future intellectual property lawsuits could require significant damages payments or prevent product sales.
• Failure to execute invention assignment agreements with employees and contractors or inability to protect trade secrets could harm product value and competitive position.
• Inadequate protection of trademarks and trade names may hinder name recognition and competitive position.
• Patent terms may not be sufficient to effectively protect products and business for an adequate period of time, with some basic patents expiring between 2025 and 2036.
• Changes in U.S. patent laws may limit the ability to obtain, defend, and/or enforce patents.
• Inability to enforce intellectual property rights throughout the world could be a challenge.
• Claims of misappropriation of third-party intellectual property or breach of non-competition agreements could negatively impact the business.
• Product candidates and operations are subject to extensive government regulation and oversight, and failure to comply could harm the business.
• Delays or failure in receiving necessary clearances or approvals for future products would adversely affect business growth.
• Failure to comply with post-marketing regulatory requirements could subject the company to enforcement actions, including substantial penalties or product recalls.
• Products must be manufactured in accordance with federal, state, and foreign regulations, and non-compliance could force recalls or production termination.
• Misuse or off-label use of products may harm reputation, lead to product liability suits, or result in costly investigations, fines, or sanctions.
• Products may cause or contribute to adverse medical events or be subject to failures/malfunctions requiring FDA reporting, with failure to report leading to sanctions.
• Relationships with customers and third-party payors will be subject to anti-kickback, fraud and abuse, and other healthcare laws, potentially exposing the company to criminal sanctions or civil penalties.
• Changes in laws or regulations relating to data protection, or non-compliance, could materially and adversely affect the business or lead to enforcement actions.
• Failure to obtain and maintain international regulatory registrations, clearances, or approvals would prevent marketing and sales outside the United States.
• Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly to obtain regulatory clearances or approvals or to manufacture, market, or distribute products.
• Healthcare reform laws could adversely affect products and financial condition.
• Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder timely development, clearance, or approval of products.
• An active, liquid, and orderly trading market for Ordinary Shares may not develop, inhibiting shareholders' ability to sell.
• The market price of Ordinary Shares may be volatile, resulting in substantial losses for investors.
• Certain recent IPOs with comparable public floats have experienced extreme volatility seemingly unrelated to underlying performance, which may make it difficult for investors to assess value.
• If operating and financial performance does not meet public guidance, the share price may decline.
• If securities analysts do not publish research or publish negative evaluations, the share price could decline.
• Future sales of Ordinary Shares could reduce the market price due to dilution.
• The company has not paid dividends in the past and does not expect to, limiting return on investment to share value appreciation.
• If additional capital is raised, shareholders may be subject to dilution.
• Insiders will continue to have substantial influence over the company after the offering, limiting other shareholders' ability to affect key transactions.
• As an emerging growth company and foreign private issuer, the company is subject to reduced reporting requirements, which could undermine investor confidence.
• The company may be a passive foreign investment company (PFIC) for U.S. federal income tax purposes, leading to negative tax consequences for U.S. taxpayers.
• Management has broad discretion over the use of IPO funds, which may not enhance operating results or share price.
• New investors will experience immediate and substantial dilution.
• Political, economic, and military instability in Israel, including the Iron Swords war, may adversely affect operations.
• Operations may be disrupted by the obligation of management or key personnel to perform military service.
• Termination or reduction of tax and other incentives from the Israeli government may increase costs and taxes.
• The company may be required to pay monetary remuneration to Israeli employees for their inventions, even if rights are assigned.
• Terms of Israeli government grants may require royalty payments and satisfaction of conditions for manufacturing/technology transfer outside Israel, with penalties for failure.
• Covenants not-to-compete may not be enforceable under Israeli law, potentially leading to added competition.
• Provisions of Israeli law and amended articles of association may delay, prevent, or impede mergers or acquisitions.
• It may be difficult to enforce U.S. court judgments against the company and its Israeli officers/directors in Israel or the U.S., or to assert U.S. securities laws claims in Israel.

Future Outlook

Regentis Biomaterials plans to complete patient enrollment for its GelrinC pivotal trial by the end of 2025 and submit its PMA application to the FDA by the end of 2027. Following potential FDA approval, the company intends to market GelrinC in the United States with a strategic partner and seek a Current Procedural Terminology (CPT) code for reimbursement. Concurrently, it will seek strategic partners in Europe for GelrinC, which already has a CE mark. The company also aims to expand its Gelrin platform technology to develop a pipeline of products for additional tissue regeneration opportunities, including GelrinP for smaller joints and GelrinV for osteoarthritis.

Management Comments

• Management believes GelrinC offers a simple and economic procedure, allowing patients to recover quickly with potentially long-term outcomes.
• Management believes that in clinical trials, GelrinC has been shown to have potentially longer-term positive outcomes of up to four years.
• Management believes that GelrinC will offer a cost-effective, off-the-shelf product that will be simple to use, requiring approximately a 10-minute procedure and a two-week recovery period.
• Management believes that the cartilage repair market is in need of an off-the-shelf solution, which it currently lacks, and that GelrinC effectively answers those needs.
• Management believes that the company has the leadership onboard to continue to build its product lines.
• Management believes that the enrollment profile of the first 47 patients in the pivotal trial is highly matched with the control patients profile, indicating a high likelihood of success in the outcome for the pivotal trial.
• Management believes that the newest patent applications will provide protection to the updated products and processes for their manufacture, even after the expiration of the basic patent estate.
• Management believes that the banks holding the company's cash and cash equivalents are financially sound, implying minimal credit risk.
• Management believes that the company's existing cash and cash equivalents, combined with the net proceeds from this offering, will be sufficient to fund operating expenses and capital expenditure requirements through March 31, 2027, including the completion of the pivotal trial for GelrinC.

Industry Context

The document highlights that the cartilage repair market is a large sector of orthopedic medicine, with an estimated annual market opportunity of about 750,000 arthroscopic knee operations in the United States, valued at $4 billion. It emphasizes an unmet need for an 'off-the-shelf' solution, which GelrinC aims to address. Current standard of care, microfracture surgery, provides only short-term relief and produces fibrous cartilage. Competing commercial therapies primarily involve expensive autologous cellular products requiring multiple procedures and cell expansion facilities, or less preferred allogeneic cadaver-sourced products. The document positions GelrinC as a simpler, more cost-effective alternative that grows natural hyaline cartilage, potentially disrupting the market by offering a single, quick procedure with long-term outcomes.

Comparison to Industry Standards

• **Microfracture Surgery (Current Gold Standard):** GelrinC's Pilot Study showed 100% greater improvement and pain reduction at two years compared to historical microfracture procedure data. Microfracture typically provides short-term relief (9-12 months) and produces fibrous cartilage, which is prone to deterioration, whereas GelrinC has been shown to grow hyaline-like cartilage.
• **MACI (Vericel Corp.):** Vericel's MACI is an autologous cellular treatment requiring two surgical procedures (biopsy for cell expansion, then reimplantation 10-12 weeks later) and costs approximately $40,000, with a reported recovery period of 6 weeks. In contrast, GelrinC is an off-the-shelf product requiring a single, approximately 10-minute surgical procedure and a two-week recovery period, making it significantly less complex, faster, and more cost-effective.
• **CartiHeals (Smith & Nephew) Agili-C:** This product, approved by the FDA in March 2022, uses a pre-formed two-layer implant (mineral scaffold and cartilage growth scaffold). It requires special fitting and drilling into the underlying bone, even if the bone is healthy, which is often unnecessary for patients with only cartilage injuries. GelrinC, being a liquid hydrogel cured in place, completely fills the defect without requiring drilling into healthy bone.
• **Allogeneic Cartilage Products (e.g., BioCartilage from Arthrex GmbH, Revaflex from ISTO Technologies Inc.):** These products are sourced from cadavers and are generally not preferred by surgeons except in unique cases, indicating a market preference for non-cadaveric solutions like GelrinC.

Management Changes

Corporate Governance

Legal Proceedings

• **CSL Behring GmbH Payment Dispute:** A dispute arose in 2019 with CSL regarding unshipped minimum purchase commitments for fibrinogen under a Framework Supply Agreement. CSL demanded $1.476 million, claiming a valid German court order. Regentis disputed the claim, arguing conditions for payment were not met and procedural errors in the German court process.
• In May 2025, the German court dismissed Regentis' annulment claim regarding the purported ruling.
• On July 4, 2025, a settlement was reached with CSL, requiring an immediate payment of $30,000, an additional payment of $300,000 post-IPO, reimbursement for certain legal expenses, and two future payments of $300,000 and $200,000 upon achievement of certain global sales milestones. A provision of $430,000 was recorded for this settlement.

Related Party Transactions

• **Convertible Loan Agreements (2020 CLAs):** The company obtained $900,000 in convertible loans between August 2020 and February 2021. An October 2024 addendum increased the principal by an additional $450,000 from certain lenders, bearing 8% interest and including a $340,000 risk premium. These loans will automatically convert into 609,888 Ordinary Shares (original 2020 CLAs) and 553,640 Ordinary Shares (additional amount + risk premium) upon a Qualified IPO.
• **Bridge Loans (October-November 2024):** The company obtained $350,000 in bridge loans from certain lenders, including Dr. Ehud Geller (Chairman) and Pini Ben Elazar (director nominee). These loans bear 8% interest and include a 30% risk premium. They were extended to August 31, 2025, and will grant warrants to purchase 140,000 Ordinary Shares upon a Qualified IPO.
• **2024 Loan Agreements (December 2023-January 2024):** The company obtained $150,000 in loans from certain lenders, including Dr. Ehud Geller and SCP Vitalife Partners (affiliated with director Jeff Dykan). These loans bear 8% interest and include a $50,000 risk premium. They were extended to August 31, 2025, and will grant warrants to purchase 61,539 Ordinary Shares upon a Qualified IPO.
• **December 2024 Loan Agreement:** The company entered a loan agreement with its Chief Executive Officer, Dr. Eli Hazum, converting $117,000 (accrued payroll + VAT) into a loan. This loan bears 8% annual interest and includes a 30% risk premium (approximately $35,100 + VAT). It was extended to August 31, 2025, and will grant warrants to purchase 55,224 Ordinary Shares upon a Qualified IPO.
• **2025 Loan Agreements (April 2025):** The company obtained $200,000 in bridge loans from certain lenders, including Dr. Ehud Geller and Pini Ben Elazar. These loans bear 8% interest and include a 50% risk premium. They mature on August 31, 2025, and will grant warrants to purchase 92,309 Ordinary Shares upon a Qualified IPO.
• **Office Lease Agreement:** The company rents its office in Herzliya, Israel, for a monthly fee of approximately $2,500 from E.G Archimedes Ltd., an entity under the control of the company's executive chairman, Dr. Ehud Geller. The agreement is in place until December 2025.
• **One-Time Payment to Chairman:** Shareholders approved a one-time payment of $500,000 to Dr. Ehud Geller for services provided since 2019, with $250,000 payable upon completion of this offering and the remainder deferred until a future fundraising.

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience immediate and substantial dilution from the IPO. Their ownership interests will be diluted by the issuance of new shares, and the terms of future financings may adversely affect their rights. The concentration of ownership by insiders (approximately 59.2% post-IPO) could limit the ability of other shareholders to influence key transactions.
• **Employees:** The company's operations in Israel are subject to political, economic, and military instability, including the Iron Swords war, which could disrupt operations if management or key personnel are called for military service. The enforceability of non-compete covenants under Israeli law may be limited, potentially leading to increased competition from former employees.
• **Customers (Healthcare Professionals and Patients):** The success of GelrinC depends on its market acceptance by healthcare professionals and patients. If physicians do not recommend the product, or if reimbursement is not secured, market penetration will be limited. Misuse or off-label use of products could lead to patient injuries and product liability suits.
• **Suppliers:** The company's reliance on single suppliers for critical materials and contract manufacturing organizations (CMOs) makes it vulnerable to supply shortages, increased costs, and quality or compliance issues, which could impact product availability and development timelines.
• **Creditors:** The company has significant outstanding indebtedness, including convertible loans and bridge loans, which will be partially repaid with IPO proceeds. The company's ability to service its remaining debt obligations depends on future cash flows and additional financing, with a going concern qualification raising doubts about its ability to meet obligations without further funding.

Next Steps

• Complete patient enrollment for the GelrinC pivotal clinical trial by the end of 2025.
• Submit the Pre-Market Approval (PMA) application for GelrinC to the FDA by the end of 2027.
• Identify and engage strategic partners in Europe to bring GelrinC to market, leveraging its existing CE mark.
• Obtain a Current Procedural Terminology (CPT) code for GelrinC to facilitate reimbursement in the United States.
• Carry out post-approval trials for GelrinC in additional cartilage injury areas, including the ankle, wrist, and elbow.
• Build on the Gelrin platform technology to broaden the product base and develop a pipeline of products for additional tissue regeneration opportunities (e.g., GelrinP, GelrinV).
• Retain a financial public relations firm within 30 days of the IPO's effective date and maintain for at least two years.
• Maintain the listing of Ordinary Shares on the NYSE American for at least three years from the IPO date.
• Maintain a system of internal accounting controls sufficient to provide reasonable assurances for financial reporting.
• Retain a nationally recognized independent registered public accounting firm for at least three years after the IPO date.

Key Dates

Keywords

Regenerative medicine, Orthopedic, Knee cartilage repair, Hydrogel, GelrinC, Initial Public Offering, IPO, Medical device, Clinical trials, FDA approval, CE mark, Biomaterials, Israel, Tissue engineering, Osteoarthritis, Microfracture, PMA submission, NYSE American